AN2 Therapeutics, Inc. (ANTX): restructuring charge — AN2 discontinues EBO-301 MAC lung study, cuts ~50% workforce, shifts pipeline focus

AN2 Therapeutics, Inc.

Phase 2/3 EBO-301 study discontinued; sputum culture conversion at Month 6: 13.2% vs 10.0% (p=0.64).
Reduction in force of ~50% of employees; expects $2-3M in severance charges.
CMO Paul Eckburg departs Aug 30, 2024; will continue as consultant with vesting.
Company shifts focus to boron chemistry platform; plans Phase 1 for Chagas, Phase 2 for melioidosis.
Cost savings expected to extend cash runway through 2027.

item 2.05 item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Paul Eckburg

Chief Medical Officer

ANTX · AN2 Therapeutics, Inc.

Effective: 2024-08-30
Filed: August 8, 2024, 7:59 PM ET

Paul Eckburg, M.D., the Company’s Chief Medical Officer, will depart the Company effective as of August 30, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Paul Eckburg departed as Chief Medical Officer at AN2 Therapeutics, Inc..

Action: departed
Role: Chief Medical Officer

Exact text from the filing

Paul Eckburg, M.D., the Company’s Chief Medical Officer, will depart the Company effective as of August 30, 2024

View on SEC.gov

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

AN2 Therapeutics, Inc. announced a restructuring with charges of approximately $2-$3 million (approximately 50% of the Company's employee workforce).

Type: restructuring
Charge: approximately $2-$3 million
Headcount: approximately 50% of the Company's employee workforce

Exact text from the filing

On August 7, 2024, the Board of Directors of AN2 Therapeutics, Inc. (the “Company”) approved a reduction in force that is intended to result in the termination of approximately 50% of the Company’s employee workforce.

View on SEC.gov

3 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

AN2 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-197047

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.